FDA Claritin Hypospadia Review Targeted For Summer Completion
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months